Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.565 USD | -3.21% | -6.73% | -64.18% |
Mar. 28 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 05 | Top Midday Gainers | MT |
Financials (USD)
Sales 2024 * | 59.17M | Sales 2025 * | 88.09M | Capitalization | 33.32M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 11M | EV / Sales 2024 * | 0.56 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.38 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
7.54
x | Employees | 176 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.99% |
1 day | -3.21% | ||
1 week | -6.73% | ||
Current month | +8.96% | ||
1 month | -1.35% | ||
3 months | -57.74% | ||
6 months | -42.36% | ||
Current year | -64.18% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 18-08-31 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 19-04-01 |
Yue Wu
BRD | Director/Board Member | 62 | 13-03-31 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 23-03-20 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 2.565 | -3.21% | 11,336 |
24-05-10 | 2.65 | +1.03% | 6,650 |
24-05-09 | 2.623 | -0.64% | 11,335 |
24-05-08 | 2.64 | +1.15% | 2,988 |
24-05-07 | 2.61 | -5.09% | 2,409 |
Delayed Quote Nasdaq, May 13, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.18% | 34.42M | |
+29.98% | 684B | |
+30.34% | 568B | |
-3.52% | 361B | |
+18.59% | 329B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.09% | 166B |
- Stock Market
- Equities
- CASI Stock